ROCKET-AF Heart Failure Subgroup Risk Index

ROCKET-AF Heart Failure Subgroup Risk Index — explanation and context This page presents an experimental composite index adapted to reflect the primary predictors and outcomes described in ROCKET-AF and its heart-failure subgroup analyses. The ROCKET-AF trial (rivaroxaban vs warfarin) enrolled a high-risk atrial fibrillation population and reported subgroup analyses examining outcomes among patients with heart failure, demonstrating that heart failure patients enrolled in ROCKET-AF had higher thromboembolic risk and different comorbidity profiles; renal dysfunction, prior stroke/TIA, and reduced left ventricular function were among factors associated with worse outcomes in subgroup reports. The index above assigns points to commonly reported adverse-outcome predictors (age ≥75, prior stroke/TIA, HF with reduced EF or advanced NYHA class, renal impairment, diabetes, hypertension, vascular disease, and persistent AF) to produce a simple summary score and illustrative risk bands.

This composite is provided solely to mirror the kinds of risk drivers described in ROCKET-AF subgroup publications and to help clinicians/learners explore how multiple risk factors combine in HF patients with AF. How to interpret this tool: The numeric score is an experimental summary of established predictors; the associated "risk band" is an approximate mapping for educational demonstration and should not be used as a validated probability of stroke, bleeding, or death. For clinical decision-making about anticoagulation or advanced therapies, use validated tools (e.g., CHA2DS2-VASc for stroke risk, validated bleeding scores), guideline recommendations, and individual patient assessment.